General Management

- February 2, 2023
- Article
How to Build a Life: The Hidden Link Between Workaholism and Mental Health

By: Arthur C. Brooks
- February 2, 2023
- Article
How to Build a Life: The Hidden Link Between Workaholism and Mental Health

By: Arthur C. Brooks
- January 2023
- Case
Natura: Weathering the Pandemic at Brazil's Cosmetic Giant

By: Brian Trelstad, Pedro Levindo and Carla Larangeira

Brazil's Natura, a multi-brand cosmetics group, has taken several measures to safeguard the livelihoods of its thousands of employees and millions of sales representatives during the COVID-19 health and economic crisis. The company has also made strides in its efforts to increase digital sales. Now the purpose-driven group must decide whether to vocalize its opposition to private companies buying COVID-19 vaccines to inoculate their employees before priority groups in Brazil's public health system.
- January 2023
- Case
Natura: Weathering the Pandemic at Brazil's Cosmetic Giant

By: Brian Trelstad, Pedro Levindo and Carla Larangeira

Brazil's Natura, a multi-brand cosmetics group, has taken several measures to safeguard the livelihoods of its thousands of employees and millions of sales representatives during the COVID-19 health and economic crisis. The company has also made strides in its efforts to increase digital sales. Now the purpose-driven group must decide whether to...
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker

How can a successful executive assess her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to find a therapeutic window for Cleave Therapeutics oncology drug was on track but faced an uncertain future. Overseeing the human trials of a refined second-generation drug candidate, Amy had led the company back from the “valley of death” after Cleave’s initial offering resulted in off-target toxicity. Still, after completing multiple dose escalation cohorts, Cleave’s scientists told Amy that they could not draw any definitive conclusions about the benefits of the drug. Amy and her team knew the importance of speed and capital in the high-risk business of oncology drug development where success often takes more resources and time than expected and competitors lurk. Nearing the close of a five-year investment window, should the thinly staffed Cleave 2.0 continue to recruit patients and clear dosing cohorts at a rapid rate, or should Amy prioritize funding and partnership discussions?
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker

How can a successful executive assess her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to find a therapeutic window for Cleave Therapeutics oncology drug was on track but faced an uncertain future. Overseeing the human trials of a refined second-generation drug candidate, Amy had led the...

About the Unit

The General Management Unit is concerned with the leadership and management of the enterprise as a whole. This concern encompasses:

the personal values and qualities of effective general managers and enterprise leaders;
the philosophies, values, and strategies that inform successful enterprises; and
the relation of enterprise to the broader community and other external constituencies.

The Unit's work is conceived and carried out principally in four interest groups, each of which has its own leadership, research agenda, and teaching programs:

Management Policy and Process
Management Information Systems
Society and Enterprise
Leadership, Values, and Corporate Responsibility

Recent Publications

How to Build a Life: The Hidden Link Between Workaholism and Mental Health

By: Arthur C. Brooks

February 2, 2023 |
Article |
The Atlantic

Citation

Natura: Weathering the Pandemic at Brazil's Cosmetic Giant

By: Brian Trelstad, Pedro Levindo and Carla Larangeira

January 2023 |
Case |
Faculty Research

Brazil's Natura, a multi-brand cosmetics group, has taken several measures to safeguard the livelihoods of its thousands of employees and millions of sales representatives during the COVID-19 health and economic crisis. The company has also made strides in its efforts to increase digital sales. Now the purpose-driven group must decide whether to vocalize its opposition to private companies buying COVID-19 vaccines to inoculate their employees before priority groups in Brazil's public health system.

Citation

Educators

LCA Action Planning: Responsibility and Accountability

By: Sandra J. Sucher and Marilyn Morgan Westner

January 2023 |
Module Note |
Faculty Research

LCA action plans integrate responsibility and accountability into decision-making and planning. This module note was designed for the LCA course and reviews six steps leaders can follow to develop a practical LCA action plan for their business. It shows how integrating an LCA perspective can help leaders make better strategic decisions when planning by helping them clarify analysis, sharpen criteria for success, and be better prepared to manage risk.

Keywords: Responsibility; Accountability; Management Challenges; Corporate Accountability; Leadership; Planning

Citation

Ethical Analysis: Honesty and Self-Interest

By: Nien-hê Hsieh and Christopher Diak

January 2023 |
Technical Note |
Faculty Research

Information asymmetry is pervasive in business and can often confer great advantage. This note distinguishes forms of deceptive behavior in the face of information asymmetry and aims to help students analyze their impermissibility.

Keywords: Ethics; Analysis; Balance and Stability

Citation

Educators

Purchase

LCA Module Overview: Customers

By: Nien-he Hsieh

January 2023 |
Module Note |
Faculty Research

Citation

Apple: Privacy vs. Safety (B)

By: Henry McGee, Nien-hê Hsieh and Christian Godwin

January 2023 |
Supplement |
Faculty Research

In 2020, as the COVID-19 pandemic swept across the globe, Apple and Google partnered to develop a contact tracing application that would collect information about users infected with the disease and notify those who they had been in contact with. While Apple/Google’s app would keep information about infection and contact private, some governments wanted more access. Apple and Google refused to provide this information, sparking a debate over what responsibilities the companies had in the realms of personal privacy and public health. This incident marked a seeming increase in privacy protections among technology companies, with Apple increasing user privacy options with its iOS 14 update and Zoom offering free end-to-end encryption. Did this indicate a permanent shift in the tension between privacy and safety?